{"id":23499,"date":"2024-07-01T10:03:00","date_gmt":"2024-07-01T14:03:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=23499"},"modified":"2026-10-24T12:54:06","modified_gmt":"2026-10-24T16:54:06","slug":"how-can-pharmaceutical-marketing-evolve-with-generic-entry-the-example-of-lipitor","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/how-can-pharmaceutical-marketing-evolve-with-generic-entry-the-example-of-lipitor\/","title":{"rendered":"Lipitor’s Patent Cliff Playbook: How Pfizer Kept 40% Market Share After Generic Entry \u2014 and What It Means for Your LOE Strategy"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

On November 30, 2011, Pfizer lost U.S. exclusivity for Lipitor. [1]<\/a> The FDA approved Ranbaxy’s generic atorvastatin on the same day. [2]<\/a> By the end of December, brand Lipitor still held just over 37% of atorvastatin prescriptions, according to IMS Health data reported by the Associated Press. [3]<\/a> A brand usually keeps about 10% of sales after generic competition starts. [4]<\/a><\/p>\n\n\n\n

That result is the source of the “40% market share” claim. The claim is partly right and often misread. The 40% figure describes prescription share in the first weeks of generic entry. It does not describe revenue, and it did not last.<\/p>\n\n\n\n

This article tests the claim against Pfizer’s SEC filings, court records, and market data from IMS Health, Wolters Kluwer, and Goldman Sachs. It then turns the record into a playbook for loss-of-exclusivity (LOE) planning. I use primary documents for every revenue figure and every legal event. I label every calculated figure as analysis. DrugPatentWatch tracks the patent and litigation records that sit behind this kind of timeline. The calculations here use Pfizer, FDA, and court documents only.<\/p>\n\n\n\n

The Short Answer<\/strong><\/h2>\n\n\n\n

Did Pfizer Really Keep 40% of Lipitor’s Market After Generic Entry?<\/strong><\/h3>\n\n\n\n

Yes, for a few weeks, and only by one measure. Brand Lipitor held between 33% and 41% of atorvastatin prescriptions in the first 13 weeks after generic entry, depending on the data source and the week. [3]<\/a> [5]<\/a> [6]<\/a> [7]<\/a> It did not hold 40% of revenue. U.S. branded Lipitor revenue fell 81% in 2012, from $5,003 million to $932 million. [8]<\/a><\/p>\n\n\n\n

\n

U.S. branded Lipitor revenue: $5,003 million in 2011 and $932 million in 2012, a decline of 81%. Source: Pfizer Inc. fourth-quarter and full-year 2012 results. [8]<\/a><\/p>\n<\/blockquote>\n\n\n\n

The Six Findings That Matter<\/strong><\/h3>\n\n\n\n
    \n
  1. Four published sources put brand Lipitor at 33% to 41% of atorvastatin prescriptions between December 2011 and early March 2012. [9]<\/a> [3]<\/a> [5]<\/a> [6]<\/a><\/li>\n\n\n\n
  2. The 40% figure existed before launch as a planning assumption. Watson’s sales projections assumed Pfizer would keep 40% of the market. [10]<\/a><\/li>\n\n\n\n
  3. U.S. branded Lipitor revenue in the fourth quarter of 2012 was 7.5% of the fourth quarter of 2011 (analysis, from Pfizer’s reported figures). [8]<\/a><\/li>\n\n\n\n
  4. The launch date was set 1,260 days (about 3.4 years) in advance. Pfizer and Ranbaxy agreed to November 30, 2011 on June 18, 2008 (analysis). [11]<\/a><\/li>\n\n\n\n
  5. Pfizer launched the $4 Lipitor copay card in December 2010, about one year before generic entry. [12]<\/a><\/li>\n\n\n\n
  6. The steepest quarterly revenue drop came after multi-source generic entry in May 2012. U.S. revenue fell 68.2% from the third quarter to the fourth quarter of 2012 (analysis). [1]<\/a> [13]<\/a> [8]<\/a><\/li>\n<\/ol>\n\n\n\n

    What the Data Shows: Brand Lipitor Share From December 2011 to March 2012<\/strong><\/h2>\n\n\n\n

    Brand Lipitor Share Measurements Compared<\/strong><\/h3>\n\n\n\n

    Table 1 lists every share measurement I found for the first 13 weeks. The sources use different data and different denominators. Do not average them.<\/p>\n\n\n\n

    Period<\/th>Reported figure<\/th>Brand Lipitor share<\/th>Source and method<\/th><\/tr><\/thead>
    Week ending December 9, 2011<\/td>Generics 59%, brand 41%<\/td>41%<\/td>Goldman Sachs, reported by NPR [9]<\/a><\/td><\/tr>
    First full week of December 2011<\/td>Two generics took 59% of sales<\/td>41% (derived)<\/td>IMS Health, reported by the Associated Press [3]<\/a><\/td><\/tr>
    End of December 2011<\/td>Brand just over 37%; Ranbaxy about 35%; Watson about 27%<\/td>37%<\/td>IMS Health, reported by the Associated Press [3]<\/a> [14]<\/a><\/td><\/tr>
    Week ending January 6, 2012<\/td>Atorvastatin 67.4% of the Lipitor market<\/td>32.6% (derived)<\/td>IMS prescription data, reported by Barclays Capital [5]<\/a><\/td><\/tr>
    About 10 weeks after launch<\/td>41% of dispensed prescriptions; 35% of payer-approved volume<\/td>41% dispensed; 35% approved<\/td>Wolters Kluwer Pharma Solutions claims data, February 15, 2012 [7]<\/a><\/td><\/tr>
    Week ending March 2, 2012<\/td>Atorvastatin 67.0% of the Lipitor market<\/td>33.0% (derived)<\/td>IMS prescription data, reported by Barclays Capital [6]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    The range is 33% to 41%. The low end comes from IMS data in January and March 2012. The high end comes from the first week of December and from claims data.<\/p>\n\n\n\n

    Where the 40% Figure Came From<\/strong><\/h3>\n\n\n\n

    The number appears in planning documents before launch. Watson’s sales projections assumed that Pfizer would keep 40% of the market and that Watson would compete with Ranbaxy. [10]<\/a> Analysts said Pfizer could keep up to 40% of Lipitor sales in the coming months. [15]<\/a><\/p>\n\n\n\n

    Watson’s chief executive had expected Pfizer to keep about 25% of Lipitor users for six months. He said it now looked like 40% to 45%, according to a November 29, 2011 report. [4]<\/a> A Pfizer executive said more than a third of patients wanted to stay on Lipitor. [4]<\/a><\/p>\n\n\n\n

    So the 40% figure had three origins: a Watson planning assumption, analyst commentary, and early IMS data. None of them measured revenue.<\/p>\n\n\n\n

    Four Ways to Measure Share After LOE (Original Framework)<\/strong><\/h3>\n\n\n\n

    Sources disagree because they measure different things. I use a four-part framework to separate them. This is my own classification, not an industry standard.<\/p>\n\n\n\n

    Statin-Class Prescription Share<\/strong><\/h4>\n\n\n\n

    This measure counts Lipitor against all statins. A New England Journal of Medicine analysis reported that Lipitor’s share of the statin market fell from 44% in 2006 to 26% in 2009. Generic simvastatin held 41% in 2009. [12]<\/a> This measure is the weakest guide to post-LOE behavior, because it includes drugs that Lipitor patients never switch to at the pharmacy counter.<\/p>\n\n\n\n

    Molecule-Level Prescription Share<\/strong><\/h4>\n\n\n\n

    This measure counts brand Lipitor against all atorvastatin, including generics. The IMS figures of 37%, 32.6%, and 33.0% use this denominator. [3]<\/a> [5]<\/a> [6]<\/a> The “40%” claim belongs here.<\/p>\n\n\n\n

    Claims-Based Dispensed and Approved Share<\/strong><\/h4>\n\n\n\n

    This measure uses pharmacy claims. Wolters Kluwer reported that Lipitor held 41% of dispensed atorvastatin prescriptions but only 35% of payer-approved volume. [7]<\/a> The gap shows that plans were already steering patients to generics.<\/p>\n\n\n\n

    Brand Revenue Retention<\/strong><\/h4>\n\n\n\n

    This measure compares brand revenue after LOE with brand revenue before LOE. It includes price, rebates, and volume. Pfizer’s first-quarter 2012 U.S. Lipitor revenue was $383 million, against $1,305 million in the first quarter of 2011. [16]<\/a> That is 29.3% retention (analysis).<\/p>\n\n\n\n

    Lipitor Patent Timeline: From the ‘893 Compound Patent to the November 30, 2011 Launch<\/strong><\/h2>\n\n\n\n

    Lipitor Patent and Exclusivity Timeline<\/strong><\/h3>\n\n\n\n

    Table 2 assembles dates from court records, SEC filings, and Pfizer releases.<\/p>\n\n\n\n

    Date<\/th>Event<\/th>Source<\/th><\/tr><\/thead>
    1987 onward<\/td>Pfizer starts obtaining patents on atorvastatin calcium<\/td>[2]<\/a><\/td><\/tr>
    1996 \/ 1997<\/td>FDA approves Lipitor in 1996; it reaches the market in 1997<\/td>[2]<\/a><\/td><\/tr>
    August 2, 2006<\/td>Federal Circuit affirms the ‘893 patent and holds claim 6 of the ‘995 patent invalid<\/td>[17]<\/a><\/td><\/tr>
    November 29, 2007<\/td>D. Del. dismisses Ranbaxy counterclaims on the ‘893 and ‘995 patents<\/td>[17]<\/a><\/td><\/tr>
    June 18, 2008<\/td>Pfizer and Ranbaxy settle; Ranbaxy license effective November 30, 2011<\/td>[11]<\/a><\/td><\/tr>
    January 6, 2009<\/td>Notice of Allowance for the reissue of the ‘995 enantiomer patent<\/td>[18]<\/a><\/td><\/tr>
    February 2009<\/td>FDA invokes its Application Integrity Policy and halts review of Ranbaxy ANDAs<\/td>[2]<\/a><\/td><\/tr>
    March 24, 2010<\/td>A Pfizer patent that Ranbaxy was enjoined from infringing expires<\/td>[2]<\/a><\/td><\/tr>
    December 2010<\/td>Pfizer launches the “Lipitor for You” $4 copay card<\/td>[12]<\/a><\/td><\/tr>
    May 2011<\/td>FDA grants an exception and expedites review of Ranbaxy’s ANDA<\/td>[2]<\/a><\/td><\/tr>
    June 2011<\/td>Reissue patent expires, including six-month pediatric exclusivity<\/td>[18]<\/a><\/td><\/tr>
    November 30, 2011<\/td>FDA approves Ranbaxy’s generic; Watson launches the authorized generic; Pfizer loses U.S. exclusivity<\/td>[2]<\/a> [19]<\/a> [1]<\/a><\/td><\/tr>
    Late May 2012<\/td>Ranbaxy’s 180-day exclusivity ends; multi-source generic competition begins<\/td>[20]<\/a> [1]<\/a><\/td><\/tr>
    November 9, 2012<\/td>Ranbaxy notifies customers of an atorvastatin recall<\/td>[21]<\/a><\/td><\/tr>
    2016 and 2017<\/td>Process and crystalline-form patents expire<\/td>[11]<\/a><\/td><\/tr>
    August 13, 2026<\/td>Third Circuit affirms judgment for Ranbaxy in the Lipitor antitrust MDL<\/td>[2]<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Pfizer v. Ranbaxy: The Litigation Record<\/strong><\/h3>\n\n\n\n

    Pfizer defended Lipitor patent challenges by Ranbaxy worldwide from 2003. [11]<\/a> Three U.S. events shaped the outcome.<\/p>\n\n\n\n

    The August 2006 Federal Circuit Ruling<\/strong><\/h4>\n\n\n\n

    On August 2, 2006, the Federal Circuit affirmed the validity of the ‘893 patent. It held that claim 6 of the ‘995 patent was invalid. [17]<\/a> The ‘893 patent (U.S. 4,681,893) covers atorvastatin. A 2008 report put its expiration in March 2010. [22]<\/a> The Supreme Court denied Ranbaxy’s certiorari petition in April 2007. [17]<\/a><\/p>\n\n\n\n

    The Reissue of the ‘995 Enantiomer Patent<\/strong><\/h4>\n\n\n\n

    Pfizer sought a reissue of the ‘995 patent to correct a technical defect. [18]<\/a> The reissue is RE40,667. Pfizer said it kept the same June 2011 expiration date, including six months of pediatric exclusivity. [18]<\/a> The District of Delaware found Ranbaxy’s counterclaims about the unissued reissue “speculative, purely hypothetical and unripe” on November 29, 2007. [17]<\/a><\/p>\n\n\n\n

    The ‘893 Reexamination Requests<\/strong><\/h4>\n\n\n\n

    Ranbaxy asked the Patent Office to reexamine the ‘893 patent in July 2007 (No. 90\/008,727). The office issued a notice of intent to issue a reexamination certificate in April 2008. Ranbaxy filed a second request on February 22, 2008 (No. 90\/009,048). The office denied it on April 9, 2008. [22]<\/a><\/p>\n\n\n\n

    The 2008 Settlement: What It Fixed and What It Did Not<\/strong><\/h3>\n\n\n\n

    Pfizer announced the Ranbaxy settlement on June 18, 2008. Ranbaxy received a license to sell generic Lipitor and Caduet in the U.S. effective November 30, 2011. Ranbaxy also held 180 days of first-filer exclusivity. [11]<\/a><\/p>\n\n\n\n

    Pfizer listed the remaining patent terms in that release. The basic compound patent expired in 2010. The enantiomer patent expired in 2011. Process and crystalline-form patents expired in 2016 and 2017. The Caduet combination patent expired in 2018. [11]<\/a><\/p>\n\n\n\n

    Pfizer said the settlement contained no reverse payments. [11]<\/a> Pfizer executive Ian Read called it “a win-win-win because it is pro-patient, pro-competition and pro-intellectual property.” [11]<\/a><\/p>\n\n\n\n

    Plaintiffs later called the agreement a reverse-payment arrangement. The Third Circuit describes that claim in its 2026 opinion. [2]<\/a> I return to that case below.<\/p>\n\n\n\n

    Why the License Date Sits Five Months After the June 2011 Expiry<\/strong><\/h3>\n\n\n\n

    The reissue patent expired in June 2011, but the Ranbaxy license began on November 30, 2011. [18]<\/a> [11]<\/a> That gap is 155 days if I count from June 28, 2011 (analysis; the sources give only “June 2011”). The NEJM authors reported that the Pfizer-Ranbaxy agreement “reportedly” delayed the first generic’s U.S. launch by five months. [12]<\/a> I did not find a primary document that explains the gap. Check the Orange Book entries for exact dates before you cite this one.<\/p>\n\n\n\n

    Why FDA Approval Arrived on Launch Day<\/strong><\/h3>\n\n\n\n

    Ranbaxy’s license date did not guarantee a product. FDA issued warning letters about Ranbaxy’s Paonta Sahib plant in 2006 and 2008. In February 2009, FDA invoked its Application Integrity Policy and halted review of Ranbaxy’s applications. [2]<\/a><\/p>\n\n\n\n

    FDA granted an exception in May 2011 and expedited review, which took about six and a half months. FDA found the application “substantially complete” in July 2011. FDA repeatedly told Ranbaxy it could not guarantee approval before November 30. [2]<\/a><\/p>\n\n\n\n

    Ranbaxy’s product entered the market on November 30, 2011, the day FDA approved it. [2]<\/a> FDA’s drug center director, Janet Woodcock, said: “We are working very hard to get generic drugs to people as soon as the law will allow.” [15]<\/a><\/p>\n\n\n\n

    How Pfizer Defended Share: The Four-Lever Playbook (Original Framework)<\/strong><\/h2>\n\n\n\n

    Pfizer used four levers at the same time. I group them as contracting, patient assistance, an authorized generic, and date control. This grouping is my own analysis.<\/p>\n\n\n\n

    Lever 1: Exclusive Dispensing Contracts With PBMs and Insurers<\/strong><\/h3>\n\n\n\n

    Pfizer offered rebates so that some insurers and pharmacy benefit managers would dispense only Lipitor for six months. Patients paid their plan’s generic copay or $4. [4]<\/a> Medco Health Solutions was named in the report. A Medco executive, Tim Wentworth, said the deal would save clients and members “over $1 billion just on this drug” in the next year. [4]<\/a><\/p>\n\n\n\n

    The NEJM authors described the same structure. Pfizer agreed with PBMs and insurers to provide Lipitor below the generic price, with generic-level copays, in return for exclusive atorvastatin prescriptions. [12]<\/a><\/p>\n\n\n\n

    Not every payer accepted. Some PBMs and plans reportedly rejected Pfizer’s offer and kept the generic. [23]<\/a><\/p>\n\n\n\n

    Lever 2: The $4 Copay Card<\/strong><\/h3>\n\n\n\n

    Pfizer launched the “Lipitor for You” card in December 2010 and set it to expire in December 2012. [12]<\/a> Insured patients could get Lipitor for $4 a month. A preferred brand copay averaged $25, and a generic copay averaged $10. [4]<\/a><\/p>\n\n\n\n

    NPR reported the same $4 figure and noted that the average brand copay without the card was about $25. [9]<\/a> Pfizer also paid pharmacies to mail card offers and to counsel patients on Lipitor’s benefits. [4]<\/a><\/p>\n\n\n\n

    The launch date matters. The card began 364 days before generic entry (analysis, counting from December 1, 2010, because the source gives only the month). [12]<\/a> Pfizer enrolled patients before the pricing change.<\/p>\n\n\n\n

    Lever 3: The Watson Authorized Generic<\/strong><\/h3>\n\n\n\n

    Pfizer granted Watson Pharmaceuticals the exclusive right to sell the authorized generic of Lipitor in the U.S. for five years, starting November 30, 2011. [20]<\/a> Pfizer manufactures all strengths and supplies Watson. Watson markets and distributes the product. Pfizer receives a share of Watson’s net sales. The agreement runs until November 30, 2016. [19]<\/a><\/p>\n\n\n\n

    One report said Pfizer keeps an estimated 70% of the authorized generic’s price. [4]<\/a> That is an estimate in a news report, not a disclosed contract term.<\/p>\n\n\n\n

    In the first few days, Watson took 97.6% of generic atorvastatin sales, according to a report relayed by Fierce Pharma. Watson and Ranbaxy together held roughly 14.6% of atorvastatin prescription volume. Ranbaxy held about 2.5%. [24]<\/a> The sources do not explain the gap, and the two figures cover different periods. By the end of December, IMS data showed Ranbaxy at about 35% and Watson at about 27%. [14]<\/a><\/p>\n\n\n\n

    Pfizer’s earnings releases credit the Watson agreement with a positive effect on Established Products revenue. They do not give a separate authorized-generic revenue figure. [16]<\/a><\/p>\n\n\n\n

    Lever 4: Control of the Entry Date<\/strong><\/h3>\n\n\n\n

    Pfizer used the 2008 settlement to fix the date of generic entry. The press release said the agreement gave “substantial certainty regarding the potential date November 30, 2011.” [11]<\/a> A fixed date let Pfizer build contracts, copay inventory, and a supply deal around one day.<\/p>\n\n\n\n

    Pharmacy Economics During the 180 Days<\/strong><\/h4>\n\n\n\n

    Pharmacy reimbursement typically falls only 10% to 15% in the first 180 days after generic launch, while acquisition cost falls faster. This is more pronounced with an authorized generic. Pharmacy gross profit per prescription almost doubles in the window. [23]<\/a> A McKesson analyst-day slide from June 2011 indicates wholesalers earn two to three times as much on a generic in that period. [23]<\/a><\/p>\n\n\n\n

    Pfizer priced the brand against that profit pool. Its statement said Lipitor would be priced “at or below the cost of a generic.” [15]<\/a><\/p>\n\n\n\n

    Payer Pushback in the First Ten Weeks<\/strong><\/h4>\n\n\n\n

    Wolters Kluwer reported that rejected Lipitor claims rose to nearly 8% in December. Patient reversals rose to nearly 10%. The firm said the increase shows plans moving patients to generics. [7]<\/a> A report analyst said Lipitor volume would likely keep falling because its 35% payer-approval share sat below its 41% dispensed share. [7]<\/a><\/p>\n\n\n\n

    Marketing Spend Before LOE<\/strong><\/h4>\n\n\n\n

    From July through September 2011, Pfizer spent almost $90 million on doctor sales calls and samples. Patient-directed advertising fell about 60% to $19 million. [4]<\/a><\/p>\n\n\n\n

    Pfizer’s Organizational Move<\/strong><\/h4>\n\n\n\n

    Starting in 2012, Pfizer reported U.S. Lipitor sales in its Established Products business unit. [1]<\/a> David Simmons, head of that unit, said more than a third of patients wanted to stay on Lipitor. [4]<\/a><\/p>\n\n\n\n

    What the Revenue Shows: Lipitor Quarterly Revenue, 2011 and 2012<\/strong><\/h2>\n\n\n\n

    Quarterly Revenue Table and Calculated Retention<\/strong><\/h3>\n\n\n\n

    Table 3 lists Pfizer’s reported branded Lipitor revenue by quarter. The retention column is my calculation.<\/p>\n\n\n\n

    Quarter<\/th>U.S. 2011<\/th>U.S. 2012<\/th>U.S. retained (analysis)<\/th>Worldwide 2011<\/th>Worldwide 2012<\/th>Worldwide retained (analysis)<\/th><\/tr><\/thead>
    Q1<\/td>1,305<\/td>383<\/td>29.3%<\/td>2,385<\/td>1,395<\/td>58.5%<\/td><\/tr>
    Q2<\/td>1,412<\/td>296<\/td>21.0%<\/td>2,591<\/td>1,220<\/td>47.1%<\/td><\/tr>
    Q3<\/td>1,470<\/td>192<\/td>13.1%<\/td>2,602<\/td>749<\/td>28.8%<\/td><\/tr>
    Q4<\/td>816<\/td>61<\/td>7.5%<\/td>1,999<\/td>584<\/td>29.2%<\/td><\/tr>
    Full year<\/td>5,003<\/td>932<\/td>18.6%<\/td>9,577<\/td>3,948<\/td>41.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Sources: first quarter [16]<\/a>, second quarter [25]<\/a>, third quarter [13]<\/a>, fourth quarter and full year [8]<\/a>. The quarters sum to the reported annual totals. I checked that sum.<\/p>\n\n\n\n

    Sequential Decline: When the Revenue Fell<\/strong><\/h3>\n\n\n\n

    Sequential change shows the timing. Using Pfizer’s quarterly U.S. figures, I calculate the following changes from the prior quarter.<\/p>\n\n\n\n